Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to
evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions
as anti-acne preparations in human subjects with facial acne vulgaris.